Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx® | Business Wire

Pharma

• First medical innovation in two decades using personalized medicine to show significant clinical results and improved outcomes for patients with ovarian cancer
• ChemoFx doubled the recurrent ovarian cancer patients with a responsive drug– a dramatic improvement to the one-in-four response rate observed in patients treated empirically
• Late-breaking data presented at Society of Gynecologic Oncology Annual Meeting

"The data from this multi-institution, blinded observational clinical trial with ChemoFx is a highly significant advancement in understanding how the biology of each patient’s tumor may hold answers for treatments that could result in improvements in survival beyond what we are seeing currently,” said Robert Holloway, MD, Medical Director of Florida Hospital Gynecologic Oncology. “Furthermore, the significance of this study from a clinical standpoint is that this test may have predictive abilities, enabling a physician to choose the most effective pharmaceutical treatment from among the available options for ovarian cancer.” "